Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409462 | 0.87 | KDM4E (0.71) | NPC1TP53RAB9AALDH1A1KDM4E | |
| SCHEMBL1409602 | 0.86 | LMNA (0.65) | NPC1TP53RAB9AALDH1A1KDM4E | |
| SCHEMBL18843662 | 0.86 | ALDH1A1 (0.68) | NPC1TP53RAB9AALDH1A1ATM | |
| SCHEMBL18843660 | 0.86 | ALDH1A1 (0.68) | NPC1TP53RAB9AALDH1A1ATM | |
| SCHEMBL4777614 | 0.86 | KDM4E (0.69) | NPC1TP53RAB9AALDH1A1KDM4E | |
| SCHEMBL22407743 | 0.86 | KDM4E (0.69) | NPC1TP53RAB9AALDH1A1KDM4E | |
| SCHEMBL14192211 | 0.85 | ALDH1A1 (0.72) | NPC1TP53RAB9AALDH1A1KDM4E | |
| Tetraxetan SCHEMBL861961 | 0.85 | SLC6A9 (0.49) | ALDH1A1KDM4ETDP1LMNASMN1; SMN2 | |
| SCHEMBL3216808 | 0.83 | ATM (0.74) | NPC1ALDH1A1KDM4EATMMEN1 | |
| SCHEMBL13846193 | 0.82 | HRH3 (0.60) | NPC1TP53RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| EP-3229848-B1 | TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP | RF THERAPEUTICS INC (CA) | 2020-08-12 | — | — | EP | disclosed |
| US-10286090-B2 | Targeted contrast agents comprising a hydrazide functional group | RF THERAPEUTICS INC. (CA) | 2019-05-14 | — | — | US | disclosed |
| US-20170340757-A1 | TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP | RF THERAPEUTICS INC. (CA) | 2017-11-30 | — | — | US | disclosed |
| US-20170340757-A1 | TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP | RF THERAPEUTICS INC. (CA) | 2017-11-30 | — | — | US | disclosed |
| US-20140065075-A1 | TARGETED CONTRAST AGENTS AND USES THEREOF | RF THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10286090-B2 | Targeted contrast agents comprising a hydrazide functional group | ANTXR2, CA4, CA14 | NPC1 1738/4885TP53 1303/4885RAB9A 1764/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | NPC1 2019/4885TP53 2714/4885RAB9A 2921/4885 |
| US-20140065075-A1 | TARGETED CONTRAST AGENTS AND USES THEREOF | ANTXR2, CALCOCO2, PAICS | NPC1 3928/4885TP53 2158/4885RAB9A 2707/4885 |
| US-20170340757-A1 | TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP | ANTXR2, CA4, CA14 | NPC1 1738/4885TP53 1303/4885RAB9A 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.